JPWO2019232484A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019232484A5 JPWO2019232484A5 JP2020565487A JP2020565487A JPWO2019232484A5 JP WO2019232484 A5 JPWO2019232484 A5 JP WO2019232484A5 JP 2020565487 A JP2020565487 A JP 2020565487A JP 2020565487 A JP2020565487 A JP 2020565487A JP WO2019232484 A5 JPWO2019232484 A5 JP WO2019232484A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- vhcdr1
- vhcdr3
- vhcdr2
- vlcdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024103786A JP2024150470A (ja) | 2018-06-01 | 2024-06-27 | 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体および使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862679703P | 2018-06-01 | 2018-06-01 | |
| US62/679,703 | 2018-06-01 | ||
| US201862773586P | 2018-11-30 | 2018-11-30 | |
| US62/773,586 | 2018-11-30 | ||
| PCT/US2019/035062 WO2019232484A1 (en) | 2018-06-01 | 2019-05-31 | Anti-pvrig/anti-tigit bispecific antibodies and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103786A Division JP2024150470A (ja) | 2018-06-01 | 2024-06-27 | 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体および使用方法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021525087A JP2021525087A (ja) | 2021-09-24 |
| JP2021525087A5 JP2021525087A5 (https=) | 2022-06-08 |
| JPWO2019232484A5 true JPWO2019232484A5 (https=) | 2022-06-08 |
| JP7646361B2 JP7646361B2 (ja) | 2025-03-17 |
Family
ID=67003669
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565487A Active JP7646361B2 (ja) | 2018-06-01 | 2019-05-31 | 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体および使用方法 |
| JP2024103786A Pending JP2024150470A (ja) | 2018-06-01 | 2024-06-27 | 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体および使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024103786A Pending JP2024150470A (ja) | 2018-06-01 | 2024-06-27 | 抗ｐｖｒｉｇ／抗ｔｉｇｉｔ二重特異性抗体および使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20190382477A1 (https=) |
| EP (1) | EP3802605A1 (https=) |
| JP (2) | JP7646361B2 (https=) |
| KR (1) | KR20210016448A (https=) |
| CN (1) | CN113039202A (https=) |
| AU (1) | AU2019276578A1 (https=) |
| BR (1) | BR112020024249A2 (https=) |
| CA (1) | CA3101019A1 (https=) |
| CL (1) | CL2020003127A1 (https=) |
| CO (1) | CO2020016619A2 (https=) |
| IL (1) | IL279053A (https=) |
| MX (1) | MX2020012797A (https=) |
| SG (1) | SG11202011461TA (https=) |
| WO (1) | WO2019232484A1 (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL272227B2 (en) * | 2017-07-27 | 2025-09-01 | iTeos Belgium SA | Anti-tigit antibodies |
| BR112021000727A2 (pt) | 2018-07-20 | 2021-04-13 | Surface Oncology, Inc. | Composições anti-cd112r e métodos |
| CN113614109A (zh) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | 双功能抗pd-1/il-7分子 |
| WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
| WO2021013068A1 (en) * | 2019-07-19 | 2021-01-28 | Wuxi Biologics (Shanghai) Co., Ltd. | Polypeptide complex for conjugation and use thereof |
| AU2020406083A1 (en) | 2019-12-17 | 2022-06-16 | Boehringer Ingelheim International Gmbh | Bifunctional molecules comprising an IL-7 variant |
| KR20220154140A (ko) | 2020-03-13 | 2022-11-21 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | Pvrig 결합 단백질 및 이의 의학적 용도 |
| CA3176497A1 (en) | 2020-05-07 | 2021-11-11 | Fatima MECHTA-GRIGORIOU | Antxr1 as a biomarker of immunosuppressive fibroblast populations and its use for predicting response to immunotherapy |
| CN115916348A (zh) | 2020-06-18 | 2023-04-04 | 基因泰克公司 | 使用抗tigit抗体和pd-1轴结合拮抗剂的治疗 |
| CA3188566A1 (en) * | 2020-07-03 | 2022-01-06 | Suzhou Alphamab Co., Ltd. | Coagulation factor xi (fxi) binding protein |
| TW202216778A (zh) | 2020-07-15 | 2022-05-01 | 美商安進公司 | Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷 |
| US11028172B1 (en) * | 2020-11-10 | 2021-06-08 | Lepu Biopharma Co., Ltd. | Anti-TIGIT antibodies and uses thereof |
| WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
| WO2022148781A1 (en) | 2021-01-05 | 2022-07-14 | Institut Curie | Combination of mcoln activators and immune checkpoint inhibitors |
| EP4284516A1 (en) * | 2021-01-28 | 2023-12-06 | Compugen Ltd. | Anti-pvrig antibodies formulations and uses thereof |
| WO2022165275A2 (en) * | 2021-01-28 | 2022-08-04 | Compugen Ltd. | Combination therapy with anti-pvrig antibodies formulations and anti-pd-1-antibodies |
| EP4292611A4 (en) * | 2021-02-09 | 2025-06-25 | Shanghai Junshi Biosciences Co., Ltd. | ANTI-CD112R ANTIBODIES AND USE THEREOF |
| US20240270840A1 (en) | 2021-02-11 | 2024-08-15 | Nectin Therapeutics Ltd. | Antibodies against cd112r and uses thereof |
| EP4320156A1 (en) | 2021-04-09 | 2024-02-14 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
| AU2022253351A1 (en) | 2021-04-09 | 2023-10-12 | Boehringer Ingelheim International Gmbh | New scaffold for bifunctional molecules with improved properties |
| CN115010800B (zh) * | 2021-06-10 | 2024-08-06 | 百奥赛图(北京)医药科技股份有限公司 | Pvrig基因人源化非人动物的构建方法及应用 |
| EP4588524A3 (en) * | 2021-07-01 | 2025-09-03 | Compugen Ltd. | Anti-tigit and anti-pvrig in monotherapy and combination treatments |
| CN118871463A (zh) | 2021-07-28 | 2024-10-29 | 基因泰克公司 | 用于治疗癌症的方法和组合物 |
| AU2022320667A1 (en) * | 2021-07-30 | 2024-03-14 | Shandong Simcere Biopharmaceutical Co., Ltd. | Anti-pvrig/anti-tigit bispecific antibody and application |
| JP2024535793A (ja) | 2021-09-15 | 2024-10-02 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | Ｐｄ－１に特異的に結合するタンパク質及びその医薬的使用 |
| CN117858903A (zh) | 2021-09-15 | 2024-04-09 | 江苏恒瑞医药股份有限公司 | 一种含抗pvrig/tigit双特异性抗体的药物组合物 |
| TW202321308A (zh) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | 使用抗ｔｉｇｉｔ抗體、抗ｃｄ３８抗體及ｐｄ—１軸結合拮抗劑治療血液癌症的方法 |
| CN114057867B (zh) * | 2021-12-14 | 2023-05-12 | 河南联科物联网科技有限公司 | 一种抗减蛋综合征的单克隆抗体及其应用 |
| CN115819582A (zh) * | 2021-12-24 | 2023-03-21 | 合肥天港免疫药物有限公司 | Pvrig的抗体或其抗原结合片段及其应用 |
| CN116925233A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 |
| CN116925222A (zh) * | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗pvrig抗体、其药物组合物及用途 |
| EP4537107A2 (en) | 2022-06-07 | 2025-04-16 | Genentech, Inc. | Method for determining the efficacy of a lung cancer treatment comprising an anti-pd-l1 antagonist and an anti-tigit antagonist antibody |
| US20260041765A1 (en) * | 2022-06-08 | 2026-02-12 | Shandong Simcere Biopharmaceutical Co., Ltd. | Pharmaceutical composition of pvrig/tigit bispecific antibody and use thereof |
| WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
| WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
| CN120513101A (zh) * | 2023-01-19 | 2025-08-19 | 山东先声生物制药有限公司 | 抗pvrig/抗tigit双特异性抗体在治疗恶性肿瘤中的用途 |
| CN120693178A (zh) | 2023-03-15 | 2025-09-23 | 上海迈晋生物医药科技有限公司 | 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途 |
| CN121358499A (zh) | 2023-03-30 | 2026-01-16 | Ose免疫疗法 | 靶向活化的免疫细胞以表达免疫细胞增强分子的基于脂质的纳米粒及其用途 |
| AU2024254671A1 (en) | 2023-03-30 | 2025-10-02 | Ose Immunotherapeutics | Method of synthesis of targeted lipid nanoparticle and uses thereof |
| EP4724495A1 (en) * | 2023-06-06 | 2026-04-15 | WuXi Biologics Ireland Limited | Anti-tigit x pvrig antibodies and uses thereof |
| AU2024288439A1 (en) * | 2023-07-07 | 2026-02-26 | D3 Bio (Wuxi) Co., Ltd. | Combination therapies for the treatment of cancer |
| WO2025068452A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025068461A1 (en) | 2023-09-29 | 2025-04-03 | Negio Therapeutics | Guanfacine derivatives and their use in treating cancer |
| WO2025132831A1 (en) | 2023-12-19 | 2025-06-26 | Universite D'aix-Marseille | N-heteroaryl derivatives and uses thereof for treating cancer |
| CN120230207A (zh) * | 2023-12-29 | 2025-07-01 | 百奥泰生物制药股份有限公司 | Pvrig结合蛋白、双特异性抗体及其应用 |
| WO2025242836A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders |
| WO2025242835A1 (en) | 2024-05-22 | 2025-11-27 | Ose Immunotherapeutics | Molecules comprising masking linkers and uses thereof for the treatment of cancer |
| WO2025262250A1 (en) | 2024-06-20 | 2025-12-26 | Negio Therapeutics | Guanfacine derivatives and their uses |
| WO2026068705A1 (en) | 2024-09-26 | 2026-04-02 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising non-glycosylated fc domains and uses thereof |
| CN120058919B (zh) * | 2025-04-29 | 2025-07-18 | 浙江大学杭州国际科创中心 | 抗裂谷热病毒Gn蛋白的单抗及在病毒检测中的应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| EP0915987A2 (en) | 1997-04-21 | 1999-05-19 | Donlar Corporation | POLY-($g(a)-L-ASPARTIC ACID), POLY-($g(a)-L-GLUTAMIC ACID) AND COPOLYMERS OF L-ASP AND L-GLU, METHOD FOR THEIR PRODUCTION AND THEIR USE |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HU230769B1 (hu) | 1999-01-15 | 2018-03-28 | Genentech Inc. | Módosított effektor-funkciójú polipeptid-változatok |
| US7449443B2 (en) | 2000-03-23 | 2008-11-11 | California Institute Of Technology | Method for stabilization of proteins using non-natural amino acids |
| US6586207B2 (en) | 2000-05-26 | 2003-07-01 | California Institute Of Technology | Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues |
| HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
| US7139665B2 (en) | 2002-02-27 | 2006-11-21 | California Institute Of Technology | Computational method for designing enzymes for incorporation of non natural amino acids into proteins |
| EA200401325A1 (ru) | 2002-04-09 | 2005-04-28 | Киова Хакко Когио Ко., Лтд. | Клетки с модифицированным геномом |
| EP1675620B1 (en) | 2003-10-09 | 2019-05-08 | Ambrx, Inc. | Polymer derivatives |
| EP2327724A3 (en) | 2004-02-02 | 2011-07-27 | Ambrx, Inc. | Modified human growth hormone polypeptides and their uses |
| US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP3050963B1 (en) | 2005-03-31 | 2019-09-18 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
| US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| JP2012525149A (ja) | 2009-04-27 | 2012-10-22 | オンコメッド ファーマシューティカルズ インコーポレイテッド | ヘテロ多量体分子を作製するための方法 |
| JP5816170B2 (ja) | 2009-06-26 | 2015-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| DK2560993T3 (da) | 2010-04-20 | 2024-10-14 | Genmab As | Heterodimeric antibody fc-containing proteins and methods for production thereof |
| PL2635607T3 (pl) | 2010-11-05 | 2020-05-18 | Zymeworks Inc. | Projekt stabilnego przeciwciała heterodimerowego z mutacjami w domenie FC |
| US9683052B2 (en) | 2011-03-25 | 2017-06-20 | Glenmark Pharmaceuticals S.A. | Hetero-dimeric immunoglobulins |
| SI2838917T1 (sl) | 2012-04-20 | 2019-11-29 | Merus Nv | Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul |
| MX2014014951A (es) * | 2012-06-06 | 2015-03-13 | Oncomed Pharm Inc | Agentes aglutinantes que modulan la trayectoria hippo y sus usos. |
| CA2898100C (en) | 2013-01-14 | 2023-10-10 | Xencor, Inc. | Novel heterodimeric proteins |
| CA2902739C (en) | 2013-03-15 | 2022-11-22 | Xencor, Inc. | Heterodimeric proteins |
| CA2916681A1 (en) | 2013-07-16 | 2015-01-22 | Genentech, Inc. | Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors |
| JP6775422B2 (ja) | 2014-03-28 | 2020-10-28 | ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、 Ｉｎｃ． | Ｃｄ３８及びｃｄ３に結合する二重特異性抗体 |
| AU2015305754B2 (en) | 2014-08-19 | 2018-10-25 | Merck Sharp & Dohme Llc | Anti-tigit antibodies |
| CN107207594B (zh) | 2014-12-23 | 2019-05-07 | 百时美施贵宝公司 | 针对tigit的抗体 |
| US10227408B2 (en) * | 2015-02-19 | 2019-03-12 | Compugen Ltd. | Anti-PVRIG antibodies and methods of use |
| EP3344657A1 (en) | 2015-09-02 | 2018-07-11 | The Regents of the University of Colorado, A Body Corporate | Compositions and methods for modulating t-cell mediated immune response |
| PL3356413T3 (pl) | 2015-10-01 | 2022-04-19 | Potenza Therapeutics, Inc. | Białka anty-tigit wiążące antygen oraz sposoby ich zastosowania |
| WO2017152088A1 (en) | 2016-03-04 | 2017-09-08 | JN Biosciences, LLC | Antibodies to tigit |
| SI3468586T1 (sl) | 2016-06-14 | 2025-01-31 | Xencor, Inc. | Bispecifična protitelesa za zaviralce kontrolnih točk |
| WO2018017864A2 (en) * | 2016-07-20 | 2018-01-25 | Oncomed Pharmaceuticals, Inc. | Pvrig-binding agents and uses thereof |
| CN110088132B (zh) | 2016-08-17 | 2020-10-27 | 康姆普根有限公司 | 抗tigit抗体，抗pvrig抗体及其组合 |
| WO2018045110A1 (en) | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| CN110799213A (zh) * | 2017-06-01 | 2020-02-14 | 康姆普根有限公司 | 三联组合抗体疗法 |
| KR102185854B1 (ko) | 2017-09-09 | 2020-12-02 | 애플 인크. | 생체측정 인증의 구현 |
-
2019
- 2019-05-31 CA CA3101019A patent/CA3101019A1/en active Pending
- 2019-05-31 BR BR112020024249-7A patent/BR112020024249A2/pt unknown
- 2019-05-31 MX MX2020012797A patent/MX2020012797A/es unknown
- 2019-05-31 EP EP19733259.6A patent/EP3802605A1/en active Pending
- 2019-05-31 AU AU2019276578A patent/AU2019276578A1/en not_active Abandoned
- 2019-05-31 CN CN201980050598.6A patent/CN113039202A/zh active Pending
- 2019-05-31 WO PCT/US2019/035062 patent/WO2019232484A1/en not_active Ceased
- 2019-05-31 KR KR1020207038135A patent/KR20210016448A/ko not_active Ceased
- 2019-05-31 SG SG11202011461TA patent/SG11202011461TA/en unknown
- 2019-05-31 US US16/428,856 patent/US20190382477A1/en active Pending
- 2019-05-31 JP JP2020565487A patent/JP7646361B2/ja active Active
-
2020
- 2020-11-29 IL IL279053A patent/IL279053A/en unknown
- 2020-12-01 CL CL2020003127A patent/CL2020003127A1/es unknown
- 2020-12-30 CO CONC2020/0016619A patent/CO2020016619A2/es unknown
-
2024
- 2024-06-27 JP JP2024103786A patent/JP2024150470A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019232484A5 (https=) | ||
| JP2021525087A5 (https=) | ||
| JP2025111463A5 (https=) | ||
| IL302078A (en) | Anti-CCR8 monoclonal antibodies and their uses | |
| JP2021534096A5 (https=) | ||
| JP2020531438A5 (ja) | Ｎｋｇ２ｄ、ｃｄ１６、およびｈｌａ−ｅに結合するタンパク質 | |
| GB2597851A (en) | Antibody molecules that bind to NKP30 and uses thereof | |
| JP2017535257A5 (https=) | ||
| JP2020521448A5 (https=) | ||
| JP2023123726A5 (https=) | ||
| JP2021533159A5 (https=) | ||
| JP2025038088A5 (https=) | ||
| JP2020522474A5 (https=) | ||
| JP2021525544A5 (https=) | ||
| JP7679399B2 (ja) | 抗ｆｌｔ３抗体及び組成物 | |
| JPWO2019157366A5 (https=) | ||
| JP2021531255A5 (https=) | ||
| JP2024024114A5 (https=) | ||
| Mohammadi et al. | A novel anti-HER2 bispecific antibody with potent tumor inhibitory effects in vitro and in vivo | |
| WO2023000791A1 (en) | Antibodies against ror1 and uses thereof | |
| JPWO2020172605A5 (https=) | ||
| TWI883571B (zh) | 標靶ｃｄ３的抗體及其用途 | |
| JPWO2020033664A5 (https=) | ||
| JPWO2021222578A5 (https=) | ||
| IL312060A (en) | Bispecific CD16A binders |